Akebia and Vifor Pharma Announce Exclusive License Agreement to Provide Vadadustat to Fresenius Medical Care in the U.S. Upon FDA Approval

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. MRVL

Go back to Akebia and Vifor Pharma Announce Exclusive License Agreement to Provide Vadadustat to Fresenius Medical Care in the U.S. Upon FDA Approval

Akebia Therapeutics (AKBA) PT Raised to $21 at Needham & Company

May 16, 2017 11:19 AM EDT

Needham & Company raised its price target on Akebia Therapeutics (NASDAQ: AKBA) to $21.00 (from $18.00) while maintaining a Buy rating. Akebia is licensing vadadustat distribution rights to Vifor Pharma for exclusive sale to Fresnius Medical Care. The deal will rapidly give vadadustat access to 40% of the... More